Alnylam Pharmaceuticals
ALNY • NASDAQ
Alnylam Pharmaceuticals is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Yvonne L. Greenstreet, with a market cap of $42.8B.
CEOYvonne L. Greenstreet
Market Cap$42.8B
Biotechnology
Healthcare
Employees2.1K
Websitealnylam.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for Alnylam Pharmaceuticals
Date
Thursday, April 30, 2026 (in 2 months)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$1.36
Revenue Estimate
$1.1B
Earnings History
Past 12 earnings reports for Alnylam Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 12, 2026 | Q4 2025 | $1.25Est: $1.20 | +4.2% | $1.1BEst: $1.2B | -4.6% |  10-K |
| Oct 30, 2025 | Q3 2025 | $2.90Est: $1.23 | +135.8% | $1.2BEst: $992.5M | +25.8% | 10-Q |
| Jul 31, 2025 | Q2 2025 | $0.32Est: -$0.16 | +300.0% | $773.7MEst: $661.0M | +17.0% | 10-Q |
| May 1, 2025 | Q1 2025 | -$0.01Est: -$1.03 | +99.0% | $594.2MEst: $585.8M | +1.4% | 10-Q |
| Feb 13, 2025 | Q4 2024 | $0.06Est: -$0.14 | +142.9% | $593.2MEst: $580.6M | +2.2% | 10-K |
| Oct 31, 2024 | Q3 2024 | -$0.50Est: -$0.93 | +46.2% | $500.9MEst: $533.1M | -6.0% | 10-Q |
| Aug 1, 2024 | Q2 2024 | $0.56Est: -$1.08 | +151.9% | $659.8MEst: $444.1M | +48.6% | 10-Q |
| May 2, 2024 | Q1 2024 | -$0.16Est: -$1.18 | +86.4% | $494.3MEst: $427.3M | +15.7% | 10-Q |
| Feb 15, 2024 | Q4 2023 | -$0.77Est: -$1.33 | +42.1% | $439.7MEst: $442.9M | -0.7% | 10-K |
| Nov 2, 2023 | Q3 2023 | $1.74Est: -$1.36 | +227.9% | $750.5MEst: $401.0M | +87.2% | — |
| Aug 3, 2023 | Q2 2023 | -$1.62Est: -$1.72 | +5.8% | $318.8MEst: $331.7M | -3.9% | 10-Q |
| May 4, 2023 | Q1 2023 | -$1.06Est: -$1.76 | +39.8% | $319.3MEst: $312.3M | +2.3% | — |